ARA-290 (Cibinetide)

ARA-290 is a short peptide based on a piece of erythropoietin, the hormone that makes red blood cells. It's built to trigger tissue-repair signals without affecting blood-cell production.

It's studied in nerve and recovery research — nerve regrowth, small-fiber neuropathy, and protection of oxygen-starved tissue.

Phase 2 studies in patients showed regrowth of small nerve fibers. These are clinical-trial findings, not approved uses.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

ARA-290 has FDA Fast Track and EU Orphan Drug designations but is not FDA-approved for sale.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Transient mild headache in trials. Bio-reagent handling protocols apply.

• Brines M et al. ARA 290 ameliorates small fiber neuropathy. Mol Med. 2015.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.